In the past decade, Beroni Group has achieved many breakthrough results in the fields of biomedicine and health technology with its profound scientific research strength and forward-looking strategic vision. From the R&D of tumor vaccine to the commercialization of novel coronavirus detection kit, from the exploration of stem cell therapy to the application of AI-based drug R&D model, Beroni Group has always been at the forefront of scientific research and innovation, contributing to human life and health.
In 2017, Beroni Group collaborated with multiple domestic and foreign research institutions to jointly promote the development of the WT-1 tumor vaccine. In 2018, Beroni Group participated in the development of PENAO (anti-cancer drug) project, led by Professor Philip Hogg, Director of the Roy Cancer Research Centre at the University of New South Wales. The team spent 10 years developing the project, which has the potential to be used as a standalone drug or in combination therapy with mTOR inhibitors. Meanwhile, Beroni Group collaborated with Professor Walter Ian Lipkin’s R&D team at Columbia University to develop the CII-ArboViroPlex Assay. This kit can detect multiple viruses and provides a powerful tool for rapid diagnosis of infectious diseases.
In 2019, the first phase clinical trial of the PENAO was successfully completed, laying a solid foundation for further research and promotion of PENAO. In 2020, facing with the severe situation of the global COVID-19 epidemic, Beroni Group responded quickly and developed the SARS-CoV-2 IgG/IgM Antibody Detection Kit, providing strong support for the prevention and control of the epidemic. Beroni Group also conducted nanoantibody research in collaboration with GenScript Biotech Corporation.
In 2021, while continuing to promote the SARS-CoV-2 IgG/IgM Antibody Detection Kit, Beroni Group developed the SARS-CoV-2 Antigen Test Kit. In 2022, Beroni Group actively explored the application of stem cell therapy in disease treatment. Since 2023, the PENAO project of Beroni Group has been progressing smoothly, and the research team has adopted the oral administration method during the trial process, and the test results are good. At the same time, Beroni Group officially launched research on AI-based drug R&D model. This model can utilize big data and machine learning techniques to provide more accurate and personalized solutions for disease diagnosis and treatment. In addition, Beroni Group actively explored the small nucleic acid drugs for the treatment of liver cirrhosis and has applied for multiple patents. In the research of anti-cancer cell therapy, preliminary clinical trials of γδ T cell therapy have been completed in China, and the results show that it is safe for treating solid tumors. More efficacy will continue to be verified through large-scale preclinical trials targeting different types of tumors. About our DC-CIK immunotherapy, we introduce advanced DC-CI cell preparation technology from Japan, adopt standardized GMP environmental leading processes and medical grade materials, and strict quality inspection. The purity of DC-CIK cells reaches 30%, and the activity is over 90%. After in-depth research by our scientific research team, NK cell therapy has been derived into NKT cell therapy and iNKT cell therapy, making them more precise and effective.
The Cell Preparation Center of Beroni Zhuhai Laboratory, located in Zhuhai, has been officially put into use. The construction standards are designed and built according to the internationally leading AABB standards, and it has the qualification to provide clinical cell preparations. It currently has four product lines for cell preparations and exosomes product line, and has established clinical research cooperation with more than ten top Grade A tertiary hospitals in China.
In the past decade, Beroni Group has not only achieved fruitful scientific research results, but also successfully developed multiple innovative and practical scientific research products, including the “Bei” series, “Sofia” series. The launch of these products not only enriches the product line of Beroni Group, but also provides consumers with more diversified and personalized choices.
In the future, Beroni Group will continue to adhere to the strategic idea of innovation driven development, continuously increasing R&D investment and innovation efforts in the fields of biomedicine and health technology. Beroni Group will actively explore the application of new technologies and methods in disease diagnosis and treatment, contributing to the global human life and health.
